Rise and shine, everyone, another busy day is on the way. We could tell because our short person rushed out the door to grab a ride to the local schoolhouse and we have already quaffed two cups of stimulation — French toast is our preference, for those tracking such things. All this means that the time has come to attack the ever-growing to-do list. So join us as we dig in. Speaking of which, here are some tidbits. Hope your day is outstanding …
The World Health Organization hopes to conduct a “full review” by the end of the year of data on the Sanofi (SNY) dengue vaccine, Reuters reports. The move comes after the company said a new analysis found its Dengvaxia vaccine could actually make future cases of the mosquito-borne virus more severe in people who were not previously infected. The issue arises after a pair of scientific papers published over the past two years suggested such a problem with the vaccine.
About the Author Reprints
Will this comment – Novartis chief executive Joseph Jimenez says “we are thinking about exiting “oral solids” portion of this business … – come as a shock to ‘friends and family’ of the late lamented ‘Ciba Gellcaps’ facility most recently known as the Novartis Suffern site?
This link is in lieu of a Pharmalot reference that I cannot seem to locate:
http://www.lohud.com/story/news/local/rockland/ramapo/2017/09/14/suffern-novartis-site-sold-18-million/665658001/